Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumour volumes in recurrent glioblastoma patients treated with bevacizumab

Trial Profile

Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumour volumes in recurrent glioblastoma patients treated with bevacizumab

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2015

At a glance

  • Drugs Imatinib (Primary)
  • Indications Glioblastoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top